Lexeo Therapeutics, Inc. (LXEO) - Dilution Analysis

10-Q filing | 81.2M shares outstanding

10-K filing | 74.1M shares outstanding

S-3 filing: This prospectus relates to the offer and resale from time to time of up to 1,250,015 shares of common stock of Lexeo Therapeutics, Inc. by the selling stockholder identified in this prospectus, including its transferees, pledgees or donees or their respective successors.

10-Q filing | 73.0M shares outstanding

10-Q filing | 54.0M shares outstanding

S-3/A filing: This prospectus relates to the offer and resale from time to time of up to 41,630,514 shares of common stock of Lexeo Therapeutics, Inc. by the selling stockholders.

S-3 filing: This prospectus relates to the issuance by Lexeo Therapeutics, Inc. of up to 20,840,394 shares of common stock issuable upon the exercise of warrants and the offer and resale from time to time of up to 41,630,514 shares of Common Stock of the Company by the selling stockholders.

8-K filing: Lexeo Therapeutics, Inc. entered into a Securities Purchase Agreement for a private placement of 20,790,120 shares of common stock and pre-funded warrants to purchase 6,963,556 shares of common stock at a price of $2.8825 per share (or $2.8824 per pre-funded warrant), with gross proceeds of approximately $80 million. ($80.0M proceeds)

10-Q filing | 33.1M shares outstanding

10-K filing | 31.8M shares outstanding

S-3 filing: Lexeo Therapeutics, Inc. files an S-3 form for a shelf offering of common stock, preferred stock, debt securities, subscription rights and purchase contracts, with a total proposed amount of $300,000,000.

POS AM filing: This POS AM filing relates to the offer and resale from time to time of up to 6,974,248 shares of common stock by selling stockholders.

10-Q filing | 33.1M shares outstanding

10-Q filing | 33.0M shares outstanding

8-K filing: Tim Van Hauwermeiren was appointed to the board of directors of Lexeo Therapeutics, Inc. on July 5, 2024, and was granted an initial stock option award for 36,000 shares.

10-Q filing | 32.9M shares outstanding

S-1 filing: This S-1 filing relates to the resale of common stock by selling stockholders; the company will not receive any proceeds from the sale. As of March 27, 2024, there are 32,948,332 shares of common stock outstanding.

10-K filing | 26.7M shares outstanding

8-K filing: Lexeo Therapeutics, Inc. entered into a Common Stock Purchase Agreement for a private placement, selling 6,278,905 shares of common stock at $15.13 per share, with gross proceeds expected to be approximately $95 million. ($95.0M proceeds)

10-Q filing | 26.6M shares outstanding

S-1/A filing: This is an S-1/A filing for an initial public offering of common stock, with underwriters granted an option to purchase up to 1,350,000 additional shares.

S-1/A filing: This is an S-1/A filing related to Lexeo Therapeutics, Inc. that includes legal opinions regarding the validity of shares and information about a 2023 Equity Incentive Plan.